Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
October 24, 2022 08:00 ET | Source: Assembly Biosciences, Inc.
Four poster presentations, including two late breaking, highlight breadth and promise of virology portfolio
Data demonstrating preclinical activity of next-generation core inhibitor ABI-4334 against hepatitis B virus supports planned advancement into clinical studies before year end
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that clinical and preclinical data from its virology portfolio will be featured in four poster presentations, including two late breaker presentations, at the upcoming American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 4-8, 2022, in Washington, DC.
The presentations will include preclinical data supporting the advancement of the company’s next-generation core inhibitor candidate, ABI-4334 (4334), into clinical development for the treatment of hepatitis B virus (HBV), with a Phase 1a trial expected to start in H2 2022. Data highlighting the preclinical characterization of Assembly Bio’s novel small molecule viral entry inhibitor for HBV and hepatitis delta virus (HDV) will also be presented. Additionally, two poster presentations accepted as late-breaking abstracts will focus on Assembly Bio’s interferon-α receptor (IFNAR) agonist research program and the ongoing Phase 2 study evaluating first-generation core inhibitor vebicorvir in combination with Arbutus Biopharma’s AB-729 in HBV.
“We look forward to presenting data at AASLD’s The Liver Meeting that demonstrate the promise of our pipeline, strength of our science and breadth of our expanded research efforts,” said William Delaney, PhD, chief scientific officer of Assembly Bio. “Notably, we will highlight preclinical data exploring the activity of our highly potent next-generation core inhibitor 4334 against the formation of cccDNA, the HBV viral reservoir. We will also present for the first time preclinical data from our oral viral entry inhibitor research program introduced earlier this year, which builds upon our core inhibitor portfolio with a complementary mechanism against HBV while also extending our research focus to HDV.”
Details of the poster presentations are as follows; presentation details on the two additional late-breaking posters will be available closer to the meeting:
Poster Presentation #1119: ABI-4334, a novel hepatitis B virus core inhibitor, accelerates capsid assembly and inhibits cccDNA formation via multiple pathways
First Author: Nuruddin Unchwaniwala, PhD, Assembly Bio
Session: Posters
Date and Time: Friday, November 4, 2022, 12:00 p.m. ET
Poster Presentation #1132: Preclinical characterization of a novel class of highly potent small molecule hepatitis B and D virus entry inhibitors
First Author: Heidi Contreras, PhD, Assembly Bio
Session: Posters
Date and Time: Friday, November 4, 2022, 12:00 p.m. ET
AASLD Presentations and Posters
Presentations and posters are expected to be made available online to conference registrants through The Liver Meeting Digital Experience™ at https://www.aasld.org/the-liver-meeting/digital-experience within 72 hours of presentation. The full posters will be available online at the “Events & Presentations” page in the “Investors” section of Assembly's website at www.assemblybio.com.